Literature DB >> 25515510

Involvement of the P2X7 purinergic receptor in inflammation: an update of antagonists series since 2009 and their promising therapeutic potential.

Davy Baudelet, Emmanuelle Lipka, Régis Millet, Alina Ghinet1.   

Abstract

The purinergic receptor P2X7 is highly expressed in immune peripheral and central cells suggesting its important role in numerous diseases characterized by inflammatory processes like cancer, or neurodegenerative pathologies in relation with modulation of the immune system. Thereby, antagonization of this receptor may be a hopeful therapeutic strategy to treat a large range of diseases. Indeed, selective P2X7 antagonists display beneficial anti-inflammatory, analgesic, and in some cases, anticancer properties. This article will review the involvement of P2X7 in the immune system, the update of P2X7 antagonists series since 2009 and their promising therapeutic potential for the treatment of several immune- related diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25515510     DOI: 10.2174/0929867322666141212120926

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  14 in total

Review 1.  Medicinal chemistry of adenosine, P2Y and P2X receptors.

Authors:  Kenneth A Jacobson; Christa E Müller
Journal:  Neuropharmacology       Date:  2015-12-12       Impact factor: 5.250

2.  Promising Therapeutic Potential of P2X7 Modulators.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2016-03-04       Impact factor: 4.345

Review 3.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

4.  Arylboronic acids inhibit P2X7 receptor function and the acute inflammatory response.

Authors:  Robson Xavier Faria; Noemi de Jesus Hiller; Juliana Pimenta Salles; Jackson Antonio Lamounier Camargos Resende; Roberta Tosta Diogo; Natalia Lidmar von Ranke; Murilo Lamim Bello; Carlos Rangel Rodrigues; Helena Carla Castro; Daniela de Luna Martins
Journal:  J Bioenerg Biomembr       Date:  2019-06-29       Impact factor: 2.945

5.  Agonists, Antagonists, and Modulators of P2X7 Receptors.

Authors:  Christa E Müller; Vigneshwaran Namasivayam
Journal:  Methods Mol Biol       Date:  2022

6.  Long non‑coding RNA BC168687 small interfering RNA reduces high glucose and high free fatty acid‑induced expression of P2X7 receptors in satellite glial cells.

Authors:  Cheng-Long Liu; Ze-Yu Deng; Er-Rong Du; Chang-Shui Xu
Journal:  Mol Med Rep       Date:  2018-02-13       Impact factor: 2.952

7.  Off-Target Anti-Inflammatory Activity of the P2X7 Receptor Antagonist AZ11645373.

Authors:  Olga V Oskolkova; Viktoria Godschachner; Valery N Bochkov
Journal:  Inflammation       Date:  2017-04       Impact factor: 4.092

8.  Effects of LncRNA BC168687 siRNA on Diabetic Neuropathic Pain Mediated by P2X7 Receptor on SGCs in DRG of Rats.

Authors:  Chenglong Liu; Jia Tao; Hui Wu; Yixin Yang; Qiang Chen; Zeyu Deng; Jiandi Liu; Changshui Xu
Journal:  Biomed Res Int       Date:  2017-10-24       Impact factor: 3.411

Review 9.  The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression.

Authors:  Geoffrey Burnstock; Gillian E Knight
Journal:  Purinergic Signal       Date:  2017-11-21       Impact factor: 3.765

Review 10.  Lung inflammation caused by inhaled toxicants: a review.

Authors:  John Wong; Bruce E Magun; Lisa J Wood
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.